Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Catalent will buy Pharmatek Labs

by Ann M. Thayer
September 19, 2016 | A version of this story appeared in Volume 94, Issue 37

Catalent is buying San Diego-based Pharmatek Laboratories for an undisclosed amount. The purchase will add early-stage dosage-form drug development capabilities, analytical services, and clinical-scale manufacturing to Catalent’s drug delivery and formulation business. In particular, Catalent will gain spray-drying technology and expand its ability to handle highly potent compounds. Pharmatek works on oral, injectable, and topical products for more than 100 customers, the companies say.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.